Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

The United States Food and Drug Administration (FDA) announced on July 29 the approval of Arcutis’ ZORYVE™ (Roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals 12 years of age or older. ZORYVE is a once-daily, steroid-free cream approved to treat mild, moderate, and severe plaque psoriasis. ZORYVE™ has proven to provide patients with rapid clearance of plaques and reduction in itch in all affected areas of the body. This is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.